Valuation: Scancell Holdings plc

Market Cap 197M 261M 229M 211M 370M 24.59B 377M 2.53B 980M 12.12B 979M 957M 42.12B P/E 2026 *
-12.7x
P/E 2027 * -24.1x
Enterprise Value 208M 274M 241M 222M 389M 25.89B 396M 2.66B 1.03B 12.76B 1.03B 1.01B 44.35B EV / Sales 2026 *
166x
EV / Sales 2027 * 88.8x
Free-Float
96.34%
Yield 2026 *
-
Yield 2027 * -
1 week-8.43%
Current month-20.50%
1 month-17.39%
3 months+61.70%
6 months+94.87%
Current year+91.92%
1 week 18.7
Extreme 18.7
22
1 month 18.18
Extreme 18.18
25
Current year 9.5
Extreme 9.5
29.5
1 year 7.86
Extreme 7.8555
29.5
3 years 7.26
Extreme 7.26
29.5
5 years 7.26
Extreme 7.26
29.5
10 years 0.11
Extreme 0.1118
29.5
Manager TitleAgeSince
Chief Executive Officer 64 18/11/2024
Chief Executive Officer 69 28/07/2021
Director of Finance/CFO 50 24/04/2026
Director TitleAgeSince
Director/Board Member 69 17/11/2010
Director/Board Member 74 23/10/2019
Director/Board Member 64 24/09/2020
Date Insider Type Main position Quantity % Market Cap.
16/09/25
Vulpes Investment Management Pte Ltd.
BuyCompany 3,150,000 0.3038%
08/08/25
Vulpes Investment Management Pte Ltd.
BuyCompany 102,236 0.0099%
04/08/25
Vulpes Investment Management Pte Ltd.
BuyCompany 4,400,000 0.4244%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-8.43%+105.41%+46.15% 261M
-0.56%+7.12%-5.15%+2.38% 46.36B
+4.95%+9.31%+363.86%+598.16% 37.88B
+0.44%+11.12%+17.47%-12.91% 31.12B
-0.64%+1.92%+3.08%+53.58% 30.61B
+0.23%-0.29%+13.24%+21.10% 24.69B
+9.90%+13.32% - - 16.25B
+1.40%+12.99%+67.11%+132.76% 14.85B
-0.18%+8.96%+11.93%+21.34% 13.58B
+2.38%+5.69%+95.85%+97.63% 12.95B
Average +1.79%+6.54%+74.76%+106.69% 22.85B
Weighted average by Cap. +1.62%+7.99%+79.77%+132.19%

Financials

2026 *2027 *
Net sales 1.25M 1.65M 1.45M 1.34M 2.34M 156M 2.39M 16.04M 6.21M 76.84M 6.2M 6.07M 267M 2.4M 3.17M 2.79M 2.57M 4.5M 299M 4.58M 30.8M 11.93M 148M 11.91M 11.65M 513M
Net income -19.23M -25.42M -22.33M -20.57M -36.07M -2.4B -36.74M -247M -95.6M -1.18B -95.45M -93.36M -4.11B -8.24M -10.89M -9.56M -8.81M -15.45M -1.03B -15.73M -106M -40.94M -506M -40.88M -39.98M -1.76B
Net Debt 10.42M 13.77M 12.09M 11.14M 19.54M 1.3B 19.9M 134M 51.77M 640M 51.69M 50.56M 2.23B 15.87M 20.98M 18.43M 16.98M 29.77M 1.98B 30.32M 204M 78.9M 976M 78.78M 77.05M 3.39B
Logo Scancell Holdings plc
Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.
Employees
60
Date Price Change Volume
26/06/26 GBX 19.00 0.00% 324,981
25/06/26 GBX 19.00 -7.32% 943,409
24/06/26 GBX 20.50 -2.38% 330,381
23/06/26 GBX 21.00 0.00% 1,860,005
22/06/26 GBX 21.00 +1.20% 841,943
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.1900GBP
Average target price
0.3100GBP
Spread / Average Target
+63.16%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCLP Stock